NICE - Endorsed Technology Appraisals 2021/2022

It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.

Technology Appraisals Endorsement Process

The Department has reviewed its process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland.  The new arrangements are detailed in following circulars, which is effective from 18th December 2013;

NICE Technology Appraisals – Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 02/13.

For information, details of the previous arrangement can be found on the following circular;

NICE Technology Appraisals and Clinical Guidelines – New Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 04/11

2021/2022

The following technology appraisals have been endorsed during 2021/22. Information on technology appraisals endorsed in previous years can be found on the homepage. 

March 2022

TA778 - Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria

TA777 - Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea

TA776 - Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea

TA775 - Dapagliflozin for treating chronic kidney disease

TA773 - Empagliflozin for treating chronic heart failure with reduced ejection fraction

TA772 - Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies

TA770 - Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer 

‘Note this guidance updates and replaces NICE Technology Appraisal TA600, which was endorsed by the DoH in October 2019’.

TA769 - Palforzia for treating peanut allergy in children and young people

February 2022

TA768 - Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs

TA767 - Ponesimod for treating relapsing–remitting multiple sclerosis

TA766 - Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma - Note this guidance updates and replaces NICE Technology Appraisal TA553, which was endorsed by the DoH in March 2019

TA765 - Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable

TA764 - Fremanezumab for preventing migraine

‘Note this guidance updates and replaces NICE Technology Appraisal TA631, which was endorsed by the DoH in July 2020’.

TA763 - Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable

TA761 - Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection

TA760 - Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer

January 2022

TA759 - Fostamatinib for treating refractory chronic immune thrombocytopenia

TA758 - Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy

TA757 - Cabotegravir with rilpivirine for treating HIV-1

TA756 - Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis

TA755 - Risdiplam for treating spinal muscular atrophy


TA754 - Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome

TA753 - Cenobamate for treating focal onset seizures in epilepsy

TA752 - Belimumab for treating active autoantibody-positive systemic lupus erythematosus

‘Note this guidance updates and replaces NICE Technology Appraisal TA397, which was endorsed by the DoH in July 2016’.

December 2021

TA751 - Dupilumab for treating severe asthma with type 2 inflammation

TA748 - Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders

TA747 - Nintedanib for treating progressive fibrosing interstitial lung diseases

TA746 - Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer

TA744 - Upadacitinib for treating moderate rheumatoid arthritis

November 2021

TA743 - Crizanlizumab for preventing sickle cell crises in sickle cell disease

TA742 - Selpercatinib for treating advanced thyroid cancer with RET alterations

TA741 - Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer

TA740 - Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer

TA739 - Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable - ‘Note this guidance updates and replaces NICE Technology Appraisal TA492, which was endorsed by the DoH in February 2019’

TA738 - Berotralstat for preventing recurrent attacks of hereditary angioedema

TA737 - Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer

TA736 - Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy  ‘Note this guidance updates and replaces NICE Technology Appraisal TA490, which was endorsed by the DoH in February 2019’

TA735 - Tofacitinib for treating juvenile idiopathic arthritis

TA734 - Secukinumab for treating moderate to severe plaque psoriasis in children and young people

October 2021

TA729 - Sapropterin for treating hyperphenylalaninaemia in phenylketonuria

TA728 - Midostaurin for treating advanced systemic mastocytosis

TA725 - Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy Note this guidance updates and replaces NICE Technology Appraisal TA579, which was endorsed by the DoH in June 2019

September 2021

TA724 - Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer

TA723 - Bimekizumab for treating moderate to severe plaque psoriasis

TA722 – Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement

TA721 - Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer

TA720 - Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma

August 2021

TA719 - Secukinumab for treating non-radiographic axial spondyloarthritis

TA718 – Ixekizumab for treating axial spondyloarthritis

TA716 - Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency

TA715 –  Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed

TA713 - Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy - Note this guidance updates and replaces NICE Technology Appraisal TA484, which was endorsed by the DoH in January 2019’

TA712 - Enzalutamide for treating hormone-sensitive metastatic prostate cancer

July 2021

TA711 - Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs

‘Note this guidance has been updated and replaced by TA815 - Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs, which was endorsed by the DoH in September 2022.’

TA710 - Ravulizumab for treating atypical haemolytic uraemic syndrome

TA709 - Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency

TA708 - Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis

TA707 – Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer

TA706 – Ozanimod for treating relapsing–remitting multiple sclerosis

June 2021

TA705 – Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer

TA704 – Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies

TA699 – Ofatumumab for treating relapsing multiple sclerosis

TA698 - Ravulizumab for treating paroxysmal nocturnal haemoglobinuria

TA697 - Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban

TA696 - Tafamidis for treating transthyretin amyloidosis with cardiomyopathy

May 2021

TA695 - Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma Note this guidance partially updates and replaces NICE Technology Appraisal TA657, which was endorsed by the DoH in December

TA694 - Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia

TA693 - Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer

TA692 - Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy Note this guidance updates and replaces NICE Technology Appraisal TA519, which was endorsed by the DoH in February 2019.

TA691 - Avelumab for untreated metastatic Merkel cell carcinoma Note this guidance partially replaces NICE Technology Appraisal TA517, which was endorsed by the DoH in February 2019.’

TA689 - Acalabrutinib for treating chronic lymphocytic leukaemia

April 2021

TA682 - Erenumab for preventing migraine

TA683 - Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer - Note this guidance updates and replaces NICE Technology Appraisal TA557, which was endorsed by the DoH in March 2019.

TA684 - Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease - Note this guidance updates and replaces NICE Technology Appraisal TA558, which was endorsed by the DoH in March 2019.

TA685 - Anakinra for treating Still’s disease

TA687 - Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy - Note this guidance updates and replaces NICE Technology Appraisal TA593, which was endorsed by the DoH in September 2019.

TA688 - Selective internal radiation therapies for treating hepatocellular carcinoma

Back to top